Contravisory Investment Management’s GSK GSK Stock Holding History

Contravisory Investment Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,763	Closed	-$52K	–	324
2022 Q3	$52K	Buy	1,763 +31	+2%	+$1.18K	0.02%	240
2022 Q2	$94K	Sell	1,732 -16	-0.9%	-$883	0.03%	218
2022 Q1	$95K	Buy	+1,748	New	+$94.9K	0.03%	222
2020 Q3	–	Sell	-1,439	Closed	-$74K	–	266
2020 Q2	$74K	Sell	1,439 -28	-2%	-$1.44K	0.03%	192
2020 Q1	$69K	Buy	1,467 +425	+41%	+$22.7K	0.03%	201
2019 Q4	$61K	Sell	1,042 -15	-1%	-$834	0.02%	218
2019 Q3	$56K	Buy	1,057 +28	+3%	+$1.44K	0.02%	224
2019 Q2	$51K	Hold	1,029	–	–	0.02%	224
2019 Q1	$54K	Hold	1,029	–	–	0.02%	209
2018 Q4	$49K	Buy	+1,029	New	+$50.7K	0.02%	202
2018 Q1	–	Sell	-14	Closed	-$1K	–	382
2017 Q4	$1K	Buy	+14	New	+$647	﹤0.01%	365

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Contravisory Investment Management's GSK Position: Q4 2022 in Review

Contravisory Investment Management sold out of GSK (GSK) in Q4 2022, closing a stake of 1,763 shares — an estimated $52K sold.

Contravisory Investment Management first reported a position in GSK in Q4 2017 and held it in 11 quarters. The position peaked at $95K in Q1 2022. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Contravisory Investment Management reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
Contravisory Investment Management sold 1,763 GSK shares in Q4 2022, an estimated $52K.
Contravisory Investment Management first reported a position in GSK in Q4 2017 and held it in 11 quarters.
Contravisory Investment Management's GSK position peaked at $95K in Q1 2022.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Contravisory Investment Management's 13F filing for Q4 2022, filed 13 Jan 2023.